

Glikazid[®]

Gliclazide BP

DESCRIPTION

Glikazid[®] is a preparation of gliclazide, a hypoglycemic agent of the sulfonylurea group. The hypoglycemic action of Gliclazide is related to an improvement in insulin secretion from the functioning beta cells of the pancreas. It potentiates the insulin release, improves the dynamics of insulin. Extra pancreatic effects of sulphonylureas have been reported and certain of these may potentiate the effects of secreted insulin. These effects include reduction in hepatic uptake of endogenous insulin and increased sensitivity of peripheral tissues of insulin.

INDICATIONS

Glikazid[®] is used in a certain form of diabetes (type 2 diabetes mellitus) in adults, when diet, exercise and weight loss alone do not have an adequate effect on keeping blood sugar at the correct level.

DOSAGE & ADMINISTRATION

Glikazid[®] MR Tablet:

The daily dose of **Glikazid[®] MR** tablet may vary from 30 to 120 mg once daily. The recommended starting dose of **Glikazid[®] MR** is 30 mg daily.

A single daily dose provides effective blood glucose control. The daily dose should not exceed 120 mg.

Dose adjustment should be carried out in steps of 30 mg, according to the blood glucose response. Each step should last for at least two weeks.

Glikazid[®] 80 Tablet:

The recommended daily dose of **Glikazid[®] 80** tablet is 80 mg to 320 mg (1 to 4 tablets). Dosage of 160 mg and above should be divided into two equal parts for twice a day administration. The total daily dose should not exceed 320 mg.

Glikazid[®] should be taken preferentially with meal.

CONTRAINDICATIONS

- Known hypersensitivity or allergy to Gliclazide, other sulfonylureas, sulfonamides
- Unstable and/or insulin dependent diabetes mellitus, particularly juvenile diabetes, diabetic ketoacidosis, diabetic pre-coma and coma
- During stress conditions such as serious infection, trauma or surgery
- In the presence of severe hepatic impairment
- In the presence of severe renal impairment
- Treatment with miconazole via systemic route or oromucosal gel
- Unstable and/or insulin dependent diabetes mellitus, particularly juvenile diabetes, diabetic ketoacidosis, diabetic pre-coma and coma
- Gliclazide is contraindicated in pregnancy. The product is also contra-indicated in breast feeding mothers.

SIDE EFFECTS

- Hypoglycemia
- Nausea, vomiting, diarrhea, epigastric fullness and gastric irritation
- Elevated liver enzyme levels (AST, ALT, alkaline phosphatase)
- Allergic reactions such as pruritus, erythema, urticaria

PRECAUTION

Care should be exercised with patients having hepatic and renal impairment and a small starting dose should be used with careful patient monitoring.

PHARMACEUTICAL PRECAUTION

Store in a dry place, away from light. Keep out of reach of children.

PACKAGING

Glikazid[®] 30 MR tablet: Box containing 3 strips of 10 tablets each. Each modified release tablet contains Gliclazide BP 30 mg.

Glikazid[®] 60 MR tablet: Box containing 2 strips of 10 tablets each. Each modified release tablet contains Gliclazide BP 60 mg.

Glikazid[®] 80 tablet: Box containing 4 strips of 10 tablets each. Each tablet contains Gliclazide BP 80 mg.

SK•F

Manufactured by

ESKAYEF BANGLADESH LIMITED

GAZIPUR, BANGLADESH

© REGD. TRADEMARK

PM03480 V03